HAE Haemonetics Corp

  1. Stocks
  2. Healthcare
  3. NYSE: HAE

Price (delayed)

$84.88

Market cap

$4.31B

P/E Ratio

33.95

Dividend/share

N/A

EPS

$2.5

Enterprise value

$4.99B

Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of ...

Highlights
The price to earnings (P/E) is 47% lower than the 5-year quarterly average of 64.1
The company's EPS rose by 33% YoY
The company's quick ratio fell by 22% QoQ and by 13% YoY
The debt is up by 14% since the previous quarter and by 14% year-on-year
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.haemonetics.com
Peers: TMO SYK BDX CERS

Key stats

What are the main financial stats of HAE
Market
Shares outstanding
50.79M
Market cap
$4.31B
Enterprise value
$4.99B
Valuations
Price to earnings (P/E)
33.95
Price to book (P/B)
4.57
Price to sales (P/S)
3.39
EV/EBIT
29.3
EV/EBITDA
18.92
EV/Sales
3.93
Earnings
Revenue
$1.27B
EBIT
$170.2M
EBITDA
$263.63M
Free cash flow
$123.92M
Per share
EPS
$2.5
Free cash flow per share
$2.44
Book value per share
$18.59
Revenue per share
$25.02
TBVPS
$23.96
Balance sheet
Total assets
$2.2B
Total liabilities
$1.26B
Debt
$870.59M
Equity
$943.32M
Working capital
$503.23M
Liquidity
Debt to equity
0.92
Current ratio
2.92
Quick ratio
1.55
Net debt/EBITDA
2.57
Margins
EBITDA margin
20.8%
Gross margin
52.9%
Net margin
10%
Operating margin
13.4%
Efficiency
Return on assets
6.2%
Return on equity
14.4%
Return on invested capital
11.4%
Return on capital employed
8.8%
Return on sales
13.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HAE stock price

How has the Haemonetics stock price performed over time
Intraday
0.84%
1 week
-1.47%
1 month
13.45%
1 year
-1.22%
YTD
-0.74%
QTD
-0.55%

Financial performance

How have Haemonetics's revenue and profit performed over time
Revenue
$1.27B
Gross profit
$671.89M
Operating income
$170.2M
Net income
$126.57M
Gross margin
52.9%
Net margin
10%
HAE's net income is up by 32% year-on-year
The operating income is up by 22% year-on-year
The net margin is up by 18% year-on-year but it is down by 3.8% since the previous quarter
The company's gross profit rose by 13% YoY and by 2.9% QoQ

Growth

What is Haemonetics's growth rate over time

Valuation

What is Haemonetics stock price valuation
HAE P/E details
P/E
33.95
P/B
4.57
P/S
3.39
EV/EBIT
29.3
EV/EBITDA
18.92
EV/Sales
3.93
The price to earnings (P/E) is 47% lower than the 5-year quarterly average of 64.1
The company's EPS rose by 33% YoY
The price to book (P/B) is 30% lower than the 5-year quarterly average of 6.5 and 7% lower than the last 4 quarters average of 4.9
The equity is up by 22% year-on-year and by 6% since the previous quarter
The stock's P/S is 25% less than its 5-year quarterly average of 4.5 and 6% less than its last 4 quarters average of 3.6
The revenue rose by 12% YoY and by 2.5% QoQ

Efficiency

How efficient is Haemonetics business performance
The company's return on assets rose by 19% YoY but it fell by 6% QoQ
HAE's return on equity is up by 13% year-on-year but it is down by 6% since the previous quarter
The company's return on invested capital rose by 11% YoY
The company's return on sales rose by 8% YoY

Dividends

What is HAE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HAE.

Financial health

How did Haemonetics financials performed over time
The total assets is 75% more than the total liabilities
The company's quick ratio fell by 22% QoQ and by 13% YoY
The total assets has grown by 17% YoY and by 9% from the previous quarter
The debt is 8% smaller than the equity
The equity is up by 22% year-on-year and by 6% since the previous quarter
The debt is up by 14% since the previous quarter and by 14% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.